Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain cancer drug shows promise in early trial

NCT ID NCT06806228

Terminated Disease control Sponsor: Petrov, Andrey Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receive S-Gboxin alongside standard therapy. Researchers will use brain scans to measure changes in tumor metabolism and size, and track survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
S-Gboxin, a drug that targets energy production in cancer cells
What this could lead to
If it works, this could point toward a new way to treat glioblastoma by blocking the energy supply of tumor cells.
What could go wrong
This is a very early, small pilot study with only 10 participants. The drug may not work or could cause side effects. The trial is currently suspended.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma diffuse midline glioma, H3 K27M-mutant giant cell glioblastoma glioblastoma glioma susceptibility 1 gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT GBM GIANT CELL GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GLIOSARCOMA

Contacts and locations

Locations

  • Kazakh Institute of Oncology and Radiology

    Almaty, 490 078, Kazakhstan

  • National Cancer Institute

    Kyiv, 33/43, Ukraine

  • Tbilisi Cancer Centre

    Tbilisi, 0198, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.